JP2014503574A5 - - Google Patents

Download PDF

Info

Publication number
JP2014503574A5
JP2014503574A5 JP2013550886A JP2013550886A JP2014503574A5 JP 2014503574 A5 JP2014503574 A5 JP 2014503574A5 JP 2013550886 A JP2013550886 A JP 2013550886A JP 2013550886 A JP2013550886 A JP 2013550886A JP 2014503574 A5 JP2014503574 A5 JP 2014503574A5
Authority
JP
Japan
Prior art keywords
compound
group
formula
optionally substituted
nitrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013550886A
Other languages
English (en)
Japanese (ja)
Other versions
JP5931926B2 (ja
JP2014503574A (ja
Filing date
Publication date
Priority claimed from FR1150651A external-priority patent/FR2970967B1/fr
Application filed filed Critical
Publication of JP2014503574A publication Critical patent/JP2014503574A/ja
Publication of JP2014503574A5 publication Critical patent/JP2014503574A5/ja
Application granted granted Critical
Publication of JP5931926B2 publication Critical patent/JP5931926B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013550886A 2011-01-27 2012-01-27 医薬としてのアザインダゾールまたはジアザインダゾール型の誘導体 Active JP5931926B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1150651A FR2970967B1 (fr) 2011-01-27 2011-01-27 Derives de type azaindazole ou diazaindazole comme medicament
FR1150651 2011-01-27
PCT/EP2012/051283 WO2012101239A1 (en) 2011-01-27 2012-01-27 Derivatives of azaindazole or diazaindazole type as medicament

Publications (3)

Publication Number Publication Date
JP2014503574A JP2014503574A (ja) 2014-02-13
JP2014503574A5 true JP2014503574A5 (cg-RX-API-DMAC10.html) 2015-02-26
JP5931926B2 JP5931926B2 (ja) 2016-06-08

Family

ID=44318089

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013550886A Active JP5931926B2 (ja) 2011-01-27 2012-01-27 医薬としてのアザインダゾールまたはジアザインダゾール型の誘導体

Country Status (30)

Country Link
US (2) US20130172360A1 (cg-RX-API-DMAC10.html)
EP (1) EP2668184B1 (cg-RX-API-DMAC10.html)
JP (1) JP5931926B2 (cg-RX-API-DMAC10.html)
KR (2) KR101923751B1 (cg-RX-API-DMAC10.html)
CN (1) CN103339129B (cg-RX-API-DMAC10.html)
AR (1) AR084935A1 (cg-RX-API-DMAC10.html)
AU (1) AU2012210467B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013018852B1 (cg-RX-API-DMAC10.html)
CA (1) CA2823824C (cg-RX-API-DMAC10.html)
CY (1) CY1120088T1 (cg-RX-API-DMAC10.html)
DK (1) DK2668184T3 (cg-RX-API-DMAC10.html)
ES (1) ES2661695T3 (cg-RX-API-DMAC10.html)
FR (1) FR2970967B1 (cg-RX-API-DMAC10.html)
HR (1) HRP20180524T1 (cg-RX-API-DMAC10.html)
HU (1) HUE037153T2 (cg-RX-API-DMAC10.html)
IL (2) IL227496B (cg-RX-API-DMAC10.html)
LT (1) LT2668184T (cg-RX-API-DMAC10.html)
MA (1) MA34903B1 (cg-RX-API-DMAC10.html)
MX (1) MX356411B (cg-RX-API-DMAC10.html)
MY (1) MY180666A (cg-RX-API-DMAC10.html)
PL (1) PL2668184T3 (cg-RX-API-DMAC10.html)
PT (1) PT2668184T (cg-RX-API-DMAC10.html)
RS (1) RS57101B1 (cg-RX-API-DMAC10.html)
RU (1) RU2600976C2 (cg-RX-API-DMAC10.html)
SI (1) SI2668184T1 (cg-RX-API-DMAC10.html)
TN (1) TN2013000293A1 (cg-RX-API-DMAC10.html)
TR (1) TR201802944T4 (cg-RX-API-DMAC10.html)
TW (1) TWI546303B (cg-RX-API-DMAC10.html)
UA (1) UA109698C2 (cg-RX-API-DMAC10.html)
WO (1) WO2012101239A1 (cg-RX-API-DMAC10.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
FR2970967B1 (fr) * 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament
CA2865071C (en) 2012-02-22 2020-06-23 Sanford-Burnham Medical Research Institute Sulfonamide compounds and uses as tnap inhibitors
NZ702747A (en) 2012-06-13 2017-03-31 Incyte Holdings Corp Substituted tricyclic compounds as fgfr inhibitors
EP2689778A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain
EP2689779A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk
WO2014026125A1 (en) * 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
LT2986610T (lt) 2013-04-19 2018-04-10 Incyte Holdings Corporation Bicikliniai heterociklai, kaip fgfr inhibitoriai
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3233840B1 (en) 2014-12-16 2018-11-21 Eudendron S.r.l. Heterocyclic derivatives modulating activity of certain protein kinases
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
SG10201913036RA (en) 2015-02-20 2020-02-27 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US10211205B2 (en) * 2016-04-27 2019-02-19 International Business Machines Corporation Field effect transistor structure for reducing contact resistance
CN108570052A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元杂环并吡嗪化合物、制备方法、中间体、组合和应用
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
KR102653799B1 (ko) * 2018-05-02 2024-04-03 제이더블유중외제약 주식회사 신규한 헤테로 사이클 유도체
EP4309737A3 (en) 2018-05-04 2024-03-27 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
EP3788046B1 (en) 2018-05-04 2025-12-10 Incyte Corporation Salts of an fgfr inhibitor
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
EP3725777A1 (en) * 2019-04-17 2020-10-21 Rottapharm Biotech S.r.l. Benzo- and pyrido-pyrazoles as protein kinase inhibitors
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CR20220169A (es) 2019-10-14 2022-10-27 Incyte Corp Heterociclos bicíclicos como inhibidores de fgfr
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
KR20220131900A (ko) 2019-12-04 2022-09-29 인사이트 코포레이션 Fgfr 억제제의 유도체
JP2023509421A (ja) * 2019-12-31 2023-03-08 アイエフエム デュー インコーポレイテッド Sting活性に関連する状態を治療するための化合物および組成物
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021197467A1 (zh) * 2020-04-02 2021-10-07 上海华汇拓医药科技有限公司 多靶点的抗肿瘤化合物及其制备方法和应用
CN116745268A (zh) 2020-11-20 2023-09-12 2692372安大略公司 苯磺酰胺衍生物及其用途
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
AR126101A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL131582A0 (en) * 1997-03-19 2001-01-28 Basf Ag Pyrrolo [2,3d] pyrimidines and their use as tyrosine kinase inhibitors
EP1215208B1 (en) 1997-10-27 2006-07-12 Agouron Pharmaceuticals, Inc. 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
PL359651A1 (en) 2000-06-22 2004-08-23 Pfizer Inc. Process for the preparation of pyrazolopyrimidinones
WO2003068773A1 (en) * 2002-02-12 2003-08-21 Glaxo Group Limited Pyrazolopyridine derivatives
DE102004061288A1 (de) * 2004-12-14 2006-06-29 Schering Ag 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel
BRPI0614884A2 (pt) * 2005-08-25 2011-04-19 Hoffmann La Roche inibidores de p38 map cinase e métodos para uso dos mesmos
CA2657287A1 (en) 2006-07-17 2008-01-24 Merck & Co., Inc. 1-hydroxy naphthyridine compounds as anti-hiv agents
SI2120932T1 (sl) 2006-12-20 2014-09-30 Nerviano Medical Sciences S.R.L. Indazolni derivati kot kinazni inhibitorji za zdravljenje raka
SI2176231T1 (sl) 2007-07-20 2017-01-31 Nerviano Medical Sciences S.R.L. Substituirani indazolni derivati, aktivni kot kinazni inhibitorji
ES2630026T3 (es) 2008-12-18 2017-08-17 Nerviano Medical Sciences S.R.L. Derivados indazólicos sustituidos activos como inhibidores de cinasa
FR2970967B1 (fr) * 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament

Similar Documents

Publication Publication Date Title
JP2014503574A5 (cg-RX-API-DMAC10.html)
JP2014510774A5 (cg-RX-API-DMAC10.html)
JP2019524883A5 (cg-RX-API-DMAC10.html)
JP2019505541A5 (cg-RX-API-DMAC10.html)
JP2016516043A5 (cg-RX-API-DMAC10.html)
JP2015522650A5 (cg-RX-API-DMAC10.html)
JP2011509309A5 (cg-RX-API-DMAC10.html)
CN109715626A (zh) 作为fgfr抑制剂的杂环化合物
JP2017509586A5 (cg-RX-API-DMAC10.html)
JP2017528467A5 (cg-RX-API-DMAC10.html)
JP2017511360A5 (cg-RX-API-DMAC10.html)
JP2010540508A5 (cg-RX-API-DMAC10.html)
JP2008510770A5 (cg-RX-API-DMAC10.html)
JP2011529054A5 (cg-RX-API-DMAC10.html)
JP2018529690A5 (cg-RX-API-DMAC10.html)
JP2016513696A5 (cg-RX-API-DMAC10.html)
JP2019522055A5 (cg-RX-API-DMAC10.html)
JP2011523412A5 (cg-RX-API-DMAC10.html)
JP2011509302A5 (cg-RX-API-DMAC10.html)
JP2014532716A5 (cg-RX-API-DMAC10.html)
JP2013542267A5 (cg-RX-API-DMAC10.html)
JP2017506666A5 (cg-RX-API-DMAC10.html)
JP2019535723A5 (cg-RX-API-DMAC10.html)
JP2006507355A5 (cg-RX-API-DMAC10.html)
JP2017519796A5 (cg-RX-API-DMAC10.html)